Skip to main navigation Skip to search Skip to main content

Quality assurance and cancer medicines in low-income and middle-income countries

  • Chloe Tuck
  • , Kwame Peprah Boaitey
  • , Amy Hai Yan Chan

Research output: Contribution to journalComment/debate/opinionResearchpeer-review

Abstract

[Extract]
Substandard medicines are medicines that fail to meet their quality standards, whereas falsified medicines are those that have been deliberately misrepresented in their identity, composition, or source.1 Both substandard and falsified medicines are a major burden on health and economic outcomes, particularly in low-income and middle-income countries (LMICs).1 WHO reports that one in ten medicines in LMICs might be substandard or falsified,1 although a systematic review suggests higher rates of 11–48%.2 These medicines impact a broad range of therapies, including cancer treatments, antibiotics, and other life-saving therapies.
Original languageEnglish
Pages (from-to)301-303
Number of pages3
JournalThe Lancet Oncology
Volume22
Issue number3
DOIs
Publication statusPublished - Mar 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Quality assurance and cancer medicines in low-income and middle-income countries'. Together they form a unique fingerprint.

Cite this